Primecap Management Co. CA Sells 873,746 Shares of LivaNova PLC (NASDAQ:LIVN)

Primecap Management Co. CA reduced its stake in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 15.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,754,060 shares of the company's stock after selling 873,746 shares during the quarter. Primecap Management Co. CA owned about 8.76% of LivaNova worth $220,161,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Nordea Investment Management AB boosted its position in LivaNova by 22.2% in the 4th quarter. Nordea Investment Management AB now owns 68,711 shares of the company's stock valued at $3,188,000 after buying an additional 12,470 shares during the last quarter. Harbor Capital Advisors Inc. acquired a new position in shares of LivaNova during the fourth quarter valued at $1,954,000. KBC Group NV increased its position in LivaNova by 130.5% in the fourth quarter. KBC Group NV now owns 99,928 shares of the company's stock worth $4,628,000 after purchasing an additional 56,580 shares during the period. Rhumbline Advisers raised its holdings in LivaNova by 0.5% during the 4th quarter. Rhumbline Advisers now owns 177,938 shares of the company's stock worth $8,240,000 after purchasing an additional 899 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in LivaNova by 17.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 621,959 shares of the company's stock valued at $32,678,000 after purchasing an additional 93,311 shares during the period. Institutional investors and hedge funds own 97.64% of the company's stock.

Remove Ads

Analysts Set New Price Targets

Several equities research analysts have recently commented on LIVN shares. The Goldman Sachs Group lowered their price target on shares of LivaNova from $64.00 to $55.00 and set a "buy" rating for the company in a research report on Monday, March 3rd. Needham & Company LLC reissued a "buy" rating and issued a $64.00 price target on shares of LivaNova in a research note on Monday. Stifel Nicolaus reduced their price target on LivaNova from $72.00 to $60.00 and set a "buy" rating on the stock in a research report on Wednesday, February 26th. StockNews.com downgraded LivaNova from a "strong-buy" rating to a "buy" rating in a report on Wednesday, February 26th. Finally, Wolfe Research cut LivaNova from an "outperform" rating to a "peer perform" rating in a report on Wednesday, February 26th. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $61.17.

LivaNova Stock Down 2.3 %

LivaNova stock traded down $0.95 during midday trading on Friday, reaching $39.48. The stock had a trading volume of 1,140,685 shares, compared to its average volume of 597,857. The stock has a market capitalization of $2.15 billion, a P/E ratio of 94.00 and a beta of 1.10. The firm's fifty day simple moving average is $45.45 and its 200-day simple moving average is $48.83. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. LivaNova PLC has a 1-year low of $36.85 and a 1-year high of $64.48.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.